Theravance

September 25, 2015November 9, 2015

GSK, Theravance To File New Drug Application in Japan For Relvar Ellipta COPD Therapy

COPD, News

On September 24, 2015, GlaxoSmithKline and Theravance announced their intention to file a Japanese New Drug Application (sJNDA) for Relvar® Ellipta® (fluticasone furoate “FF”/vilanterol “VI” or “FF/VI”) for the treatment of ... Read more

September 14, 2015November 9, 2015

GSK and Theravance’s SUMMIT COPD CV Survival Study Fails to Achieve Primary Endpoint

COPD, News

GlaxoSmithKline and Theravance, Inc. have announced results from the Study to Understand Mortality and MorbidITy (SUMMIT) in chronic obstructive pulmonary disease (COPD). This was a Phase 3 clinical trial of ... Read more

May 5, 2015November 6, 2015

FDA Approves BREO® ELLIPTA® To Treat Adults With Asthma In The US

Asthma, News

GlaxoSmithKline and Theravance, Inc. recently announced that the FDA has approved BREO® ELLIPTA® (fluticasone furoate/vilanterol ) as a once-daily treatment of asthma for patients aged 18 and older. However, Breo ... Read more

May 20, 2014November 11, 2015

Anoro COPD Treatment Gets Marketing Authorization in Europe

COPD, News

The European Commission has granted marketing authorization for Anoro (Umeclidinium/Vilanterol), a chronic obstructive pulmonary disease (COPD) treatment, which is currently licensed in Europe as UMEC/VI55mcg/22mcg. GlaxoSmithKline and Theravance announced the now-authorized combination ... Read more